Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tangshen Prescription for Early Stage Diabetic Kidney Disease
NCT03009864Phase 1Unknown
- Sponsor
- Guang'anmen Hospital
- Start
- Jan 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic kidney disease (DKD) comparing Tangshen Prescription with Placebo (2 arms). Primary endpoint: Changes of Albumin-to-Creatinine Ratio at 24 weeks. Status: unknown.
02
Drugs
Tangshen Qushi Formula
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT03009864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009864.